Breast cancer is a heterogeneous disease and four main clinicopathological groups (luminal A-like, luminal B-like, HER2-positive (non-luminal), and triple-negative) are defined based on the expression of ERs, progesterone receptors (PRs), human epidermal growth factor receptor 2 (ERBB2/HER2), and Ki67.29 This evidence concerns the gene PGR and breast cancer.